Meningococcal Vaccines Market: Infants, Adolescents, and Young Adults Primary Target Groups: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

Meningococcal Vaccines Market: Infants, Adolescents, and Young Adults Primary Target Groups: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

This Future Market Insights (FMI) report examines the global meningococcal vaccines market for the period 2013–2028. The primary objective of the report is to offer insights into market opportunity for meningitis vaccines and pipeline developments in the meningitis vaccines market. The global meningitis vaccines market has witnessed spontaneous changes in the immunisation landscape after the launch of new vaccines and initiation of public-private alliances to widen immunisation coverage. Meningococcal disease is prevalent in infants and young children. According to Centre for Disease Control and Prevention (CDC), over half of the bacterial meningitis cases occur in children less than five years of age. Approximately 10%-20% of these patients suffer from the severe consequences of meningitis including permanent damage and disability.

The market for meningococcal vaccines is primarily driven by enhanced access to vaccines in middle income countries, growing investment by manufacturers and governments to expand vaccine production, and mass immunisation campaigns. However, insufficient meningococcal immunisation coverage in low-income countries and restricted access due to stringent regulations are some of the factors limiting revenue growth of the global meningococcal vaccines market.

The global meningococcal vaccines market has been segmented on the basis of:

Product Type

Age Group

Distribution Channel

Region

The report analyses the global meningococcal vaccines market in terms of value (US$ Mn). The report begins with the market definition and explains the different types and causes of meningitis, highlighting bacterial meningitis. This section also explains the prevalence of different serogroups of N. meningitides across key regions. The journey of vaccine manufacturing explains the complex chain involving different nodes in the market and highlights how vaccines reach the market. The market viewpoint section includes FMI’s analysis on key trends, drivers, opportunities, trends and macro factors influencing the global market. Opportunity analysis provided in the section better equips clients with crystal clear decision making insights. Pipeline analysis provided in the subsequent section helps clients identify future competitors in the global market.

The report analyses the market based on regions and presents a comprehensive forecast in terms of value (US$ Mn) for the next 10 years. Regions covered in the report include:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan (APEJ)

Japan

The Middle East and Africa (MEA)

Each of these section analyses the various regional markets by product type, age group, distribution channel and country. Regional introductory sections provide key insights on market dynamics for each region. These sections are mainly designed to provide the current scenario of meningococcal vaccines market and forecast for 2018-2028. A section on representative market participants presents a list of companies operating in each region, competitive landscape and intensity map of their presence in each region.

We have incorporated a robust methodology to substantiate our research

To arrive at the market size, we have used our in-house epidemiology data-based model to estimate the meningococcal vaccines market size. We have adopted the bottom-up approach to forecast the meningococcal vaccines market. Weighted average selling price has been considered to estimate the market size of various product types mentioned in the scope of the study. The country price is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of each assessed country. The forecast presented in the report provides total revenue of currently approved meningococcal vaccine products over 2018–2028. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, a ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key differentiators among the competitor firms. Market structure analysis provides tier wise breakdown of total market revenue. The section also provides company share analysis and brand share analysis for key market players. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the various market segments. Detailed profiles of players operating in global meningitis vaccines market are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to the market and a strategic overview.

The next section of report analyses the market based on product types and presents the forecast in terms of value for the next 10 years. Meningococcal vaccine product types covered in the report include:

Polysaccharide Vaccines

Conjugate Vaccines

The next section of the report analyses the market based on age group and provides forecast in terms of value for the next 10 years. Based on age groups, the global market has been segmented in to

Infants

Children

Adolescents & Young Adults

Adults

The next section of the report analyses the market based on distribution channel for meningococcal vaccine products and provides forecast in terms of value for the next 10 years. Distribution channels covered in this report are:

Pharmacies

Community Clinics

Public Health Agencies

Others (hospital pharmacy, private market etc.)

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis to help clients identify real market opportunities.


1. Executive Summary
1.1. Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Meningococcal Vaccines Market View Point Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Epidemiology of Meningococcal Disease
3.4. Pricing Analysis
3.5. Regulatory Scenario
4. Global Meningococcal Vaccines Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
4.4. Trends
5. North America Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
5.1. Introduction
5.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
5.2.1. U.S.
5.2.2. Canada
5.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
5.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
5.4.1. Polysaccharide Meningococcal Vaccines
5.4.2. Conjugate Meningococcal Vaccines
5.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
5.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
5.6.1. Infants
5.6.2. Children
5.6.3. Adolescents & young Adults
5.6.4. Adults
5.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
5.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
5.8.1. Community Clinics
5.8.2. Pharmacies
5.8.3. Public Health Agencies
5.8.4. Others
5.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
5.10. Drivers and Restraints: Impact Analysis
5.11. Market Attractiveness Analysis
5.11.1. By Country
5.11.2. By Product Type
5.11.3. By Age Group
5.11.4. By Distribution Channel
5.12. Key Representative Market Participants
5.13. Market Presence (Intensity Map)
5.14. Company Share Analysis (2017)
6. Latin America Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
6.2.1. Brazil
6.2.2. Mexico
6.2.3. Rest of Latin America
6.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
6.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
6.4.1. Polysaccharide Meningococcal Vaccines
6.4.2. Conjugate Meningococcal Vaccines
6.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
6.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
6.6.1. Infants
6.6.2. Children
6.6.3. Adolescents & young Adults
6.6.4. Adults
6.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
6.8.1. Community Clinics
6.8.2. Pharmacies
6.8.3. Public Health Agencies
6.8.4. Others
6.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
6.10. Drivers and Restraints: Impact Analysis
6.11. Market Attractiveness Analysis
6.11.1. By Country
6.11.2. By Product Type
6.11.3. By Age Group
6.11.4. By Distribution Channel
6.12. Key Representative Market Participants
6.13. Market Presence (Intensity Map)
6.14. Company Share Analysis (2017)
7. Western Europe Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
Market forecast and analysis in EU5, Nordic, Benelux, and rest of Western Europe
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
7.2.1. Germany
7.2.2. Italy
7.2.3. France
7.2.4. Spain
7.2.5. U.K.
7.2.6. Rest of Western Europe
7.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
7.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
7.4.1. Polysaccharide Meningococcal Vaccines
7.4.2. Conjugate Meningococcal Vaccines
7.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
7.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
7.6.1. Infants
7.6.2. Children
7.6.3. Adolescents & young Adults
7.6.4. Adults
7.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
7.8.1. Community Clinics
7.8.2. Pharmacies
7.8.3. Public Health Agencies
7.8.4. Others
7.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
7.10. Drivers and Restraints: Impact Analysis
7.11. Market Attractiveness Analysis
7.11.1. By Country
7.11.2. By Product Type
7.11.3. By Age Group
7.11.4. By Distribution Channel
7.12. Key Representative Market Participants
7.13. Market Presence (Intensity Map)
7.14. Company Share Analysis (2017)
8. Eastern Europe Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
8.2.1. Russia
8.2.2. Poland
8.2.3. Rest of Eastern Europe
8.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
8.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
8.4.1. Polysaccharide Meningococcal Vaccines
8.4.2. Conjugate Meningococcal Vaccines
8.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
8.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
8.6.1. Infants
8.6.2. Children
8.6.3. Adolescents & young Adults
8.6.4. Adults
8.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
8.8.1. Community Clinics
8.8.2. Pharmacies
8.8.3. Public Health Agencies
8.8.4. Others
8.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
8.10. Drivers and Restraints: Impact Analysis
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Product Type
8.11.3. By Age Group
8.11.4. By Distribution Channel
8.12. Key Representative Market Participants
8.13. Market Presence (Intensity Map)
8.14. Company Share Analysis (2017)
9. Asia Pacific excluding Japan Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
9.2.1. China
9.2.2. India
9.2.3. Australia and New Zealand
9.2.4. Rest of APEJ
9.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
9.4.1. Polysaccharide Meningococcal Vaccines
9.4.2. Conjugate Meningococcal Vaccines
9.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
9.6.1. Infants
9.6.2. Children
9.6.3. Adolescents & young Adults
9.6.4. Adults
9.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
9.8.1. Community Clinics
9.8.2. Pharmacies
9.8.3. Public Health Agencies
9.8.4. Others
9.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
9.10. Drivers and Restraints: Impact Analysis
9.11. Market Attractiveness Analysis
9.11.1. By Country
9.11.2. By Product Type
9.11.3. By Age Group
9.11.4. By Distribution Channel
9.12. Key Representative Market Participants
9.13. Market Presence (Intensity Map)
9.14. Company Share Analysis (2017)
10. Japan Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2012–2016
10.2.1. Polysaccharide Meningococcal Vaccines
10.2.2. Conjugate Meningococcal Vaccines
10.2.3. Combination Meningococcal Vaccines
10.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
10.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
10.4.1. Polysaccharide Meningococcal Vaccines
10.4.2. Conjugate Meningococcal Vaccines
10.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
10.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
10.6.1. Infants
10.6.2. Children
10.6.3. Adolescents & young Adults
10.6.4. Adults
10.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
10.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
10.8.1. Community Clinics
10.8.2. Pharmacies
10.8.3. Public Health Agencies
10.8.4. Others
10.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
10.10. Drivers and Restraints: Impact Analysis
10.11. Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Product Type
10.11.3. By Age Group
10.11.4. By Distribution Channel
10.12. Key Representative Market Participants
10.13. Market Presence (Intensity Map)
10.14. Company Share Analysis (2017)
11. Middle East & Africa Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
11.2.1. GCC Countries
11.2.2. South Africa
11.2.3. Rest of MEA
11.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
11.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
11.4.1. Polysaccharide Meningococcal Vaccines
11.4.2. Conjugate Meningococcal Vaccines
11.5. Market Size (US$ Mn) and Forecast By Product Type, 2018–2028
11.6. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
11.6.1. Infants
11.6.2. Children
11.6.3. Adolescents & young Adults
11.6.4. Adults
11.7. Market Size (US$ Mn) and Forecast By Age Group, 2018–2028
11.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
11.8.1. Community Clinics
11.8.2. Pharmacies
11.8.3. Public Health Agencies
11.8.4. Others
11.9. Market Size (US$ Mn) and Forecast By Distribution Channels, 2018–2028
11.10. Drivers and Restraints: Impact Analysis
11.11. Market Attractiveness Analysis
11.11.1. By Country
11.11.2. By Product Type
11.11.3. By Age Group
11.11.4. By Distribution Channel
11.12. Key Representative Market Participants
11.13. Market Presence (Intensity Map)
11.14. Company Share Analysis (2017)
12. Forecast Factors: Relevance and Impact
13. Forecast Assumptions
14. Competition Landscape
14.1. Market Structure
14.2. Market Share Analysis, 2017
14.3. Competition Dashboard
14.4. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
14.4.1. GlaxoSmithKline plc.
14.4.2. Pfizer, Inc.
14.4.3. Sanofi SA
14.4.4. Serum Institute of India Ltd.
15. Global Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028, By Region
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2017
15.2.1. North America
15.2.2. Latin America
15.2.3. Western Europe
15.2.4. Eastern Europe
15.2.5. Asia Pacific excluding Japan
15.2.6. Japan
15.2.7. Middle East & Africa
15.3. Market Size (US$ Mn) Forecast By Region, 2018–2028
15.4. Market Attractiveness Analysis By Region
16. Global Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028, By Product Type
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013–2017
16.2.1. Polysaccharide Meningococcal Vaccines
16.2.2. Conjugate Meningococcal Vaccines
16.3. Market Size (US$ Mn) Forecast By Product Type, 2018–2028
16.4. Market Attractiveness Analysis By Product Type
17. Global Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028, By Age Group
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis By Age Group, 2013–2017
17.2.1. Infants
17.2.2. Children
17.2.3. Adolescents & young Adults
17.2.4. Adults
17.3. Market Size (US$ Mn) Forecast By Age Group, 2018–2028
17.4. Market Attractiveness Analysis By Age Group
18. Global Meningococcal Vaccines Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channels
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
18.2.1. Community Clinics
18.2.2. Pharmacies
18.2.3. Public Health Agencies
18.2.4. Others
18.3. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
18.4. Market Attractiveness Analysis By Distribution Channels
19. Global Meningococcal Vaccines Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
19.3. Market Value Chain Analysis
20 Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings